528 related articles for article (PubMed ID: 36107794)
1. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y;
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794
[TBL] [Abstract][Full Text] [Related]
2. Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection - United States, August 2022.
O'Shea J; Filardo TD; Morris SB; Weiser J; Petersen B; Brooks JT
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1023-1028. PubMed ID: 35951495
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
[TBL] [Abstract][Full Text] [Related]
4. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
DeLaurentis CE; Kiser J; Zucker J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026
[TBL] [Abstract][Full Text] [Related]
5. A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak.
Almehmadi M; Allahyani M; Alsaiari AA; Alshammari MK; Alharbi AS; Hussain KH; Alsubaihi LI; Kamal M; Alotaibi SS; Alotaibi AN; Aldhafeeri AA; Imran M
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146675
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic Features of the Monkeypox Outbreak and the Public Health Response - United States, May 17-October 6, 2022.
Kava CM; Rohraff DM; Wallace B; Mendoza-Alonzo JL; Currie DW; Munsey AE; Roth NM; Bryant-Genevier J; Kennedy JL; Weller DL; Christie A; McQuiston JH; Hicks P; Strid P; Sims E; Negron ME; Iqbal K; Ellington S; Smith DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1449-1456. PubMed ID: 36355615
[TBL] [Abstract][Full Text] [Related]
7. Epidemiologic and Clinical Characteristics of Monkeypox Cases - United States, May 17-July 22, 2022.
Philpott D; Hughes CM; Alroy KA; Kerins JL; Pavlick J; Asbel L; Crawley A; Newman AP; Spencer H; Feldpausch A; Cogswell K; Davis KR; Chen J; Henderson T; Murphy K; Barnes M; Hopkins B; Fill MA; Mangla AT; Perella D; Barnes A; Hughes S; Griffith J; Berns AL; Milroy L; Blake H; Sievers MM; Marzan-Rodriguez M; Tori M; Black SR; Kopping E; Ruberto I; Maxted A; Sharma A; Tarter K; Jones SA; White B; Chatelain R; Russo M; Gillani S; Bornstein E; White SL; Johnson SA; Ortega E; Saathoff-Huber L; Syed A; Wills A; Anderson BJ; Oster AM; Christie A; McQuiston J; McCollum AM; Rao AK; Negrón ME;
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1018-1022. PubMed ID: 35951487
[TBL] [Abstract][Full Text] [Related]
8. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate.
Warner BM; Klassen L; Sloan A; Deschambault Y; Soule G; Banadyga L; Cao J; Strong JE; Kobasa D; Safronetz D
Sci Transl Med; 2022 Nov; 14(673):eade7646. PubMed ID: 36318038
[TBL] [Abstract][Full Text] [Related]
10. Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or Without Known Epidemiologic Link to Monkeypox - United States, 2022.
Minhaj FS; Petras JK; Brown JA; Mangla AT; Russo K; Willut C; Lee M; Beverley J; Harold R; Milroy L; Pope B; Gould E; Beeler C; Schneider J; Mostafa HH; Godfred-Cato S; Click ES; Borah BF; Galang RR; Cash-Goldwasser S; Wong JM; McCormick DW; Yu PA; Shelus V; Carpenter A; Schatzman S; Lowe D; Townsend MB; Davidson W; Wynn NT; Satheshkumar PS; O'Connor SM; O'Laughlin K; Rao AK; McCollum AM; Negrón ME; Hutson CL; Salzer JS; ;
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(36):1155-1158. PubMed ID: 36074752
[TBL] [Abstract][Full Text] [Related]
11. Tecovirimat for the treatment of severe Mpox in Germany.
Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
[TBL] [Abstract][Full Text] [Related]
12. Oral Tecovirimat for the Treatment of Smallpox.
Grosenbach DW; Honeychurch K; Rose EA; Chinsangaram J; Frimm A; Maiti B; Lovejoy C; Meara I; Long P; Hruby DE
N Engl J Med; 2018 Jul; 379(1):44-53. PubMed ID: 29972742
[TBL] [Abstract][Full Text] [Related]
13. Monkeypox (mpox) virus: Classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis.
Karagoz A; Tombuloglu H; Alsaeed M; Tombuloglu G; AlRubaish AA; Mahmoud A; Smajlović S; Ćordić S; Rabaan AA; Alsuhaimi E
J Infect Public Health; 2023 Apr; 16(4):531-541. PubMed ID: 36801633
[TBL] [Abstract][Full Text] [Related]
14. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.
Rao AK; Schrodt CA; Minhaj FS; Waltenburg MA; Cash-Goldwasser S; Yu Y; Petersen BW; Hutson C; Damon IK
MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(9):232-243. PubMed ID: 36862595
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Monkeypox Among Unvaccinated Persons Compared with Persons Receiving ≥1 JYNNEOS Vaccine Dose - 32 U.S. Jurisdictions, July 31-September 3, 2022.
Payne AB; Ray LC; Kugeler KJ; Fothergill A; White EB; Canning M; Farrar JL; Feldstein LR; Gundlapalli AV; Houck K; Kriss JL; Lewis NM; Sims E; Smith DK; Spicknall IH; Nakazawa Y; Damon IK; Cohn AC; Payne DC
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(40):1278-1282. PubMed ID: 36201401
[TBL] [Abstract][Full Text] [Related]
16. Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022.
Miller MJ; Cash-Goldwasser S; Marx GE; Schrodt CA; Kimball A; Padgett K; Noe RS; McCormick DW; Wong JM; Labuda SM; Borah BF; Zulu I; Asif A; Kaur G; McNicholl JM; Kourtis A; Tadros A; Reagan-Steiner S; Ritter JM; Yu Y; Yu P; Clinton R; Parker C; Click ES; Salzer JS; McCollum AM; Petersen B; Minhaj FS; Brown E; Fischer MP; Atmar RL; DiNardo AR; Xu Y; Brown C; Goodman JC; Holloman A; Gallardo J; Siatecka H; Huffman G; Powell J; Alapat P; Sarkar P; Hanania NA; Bruck O; Brass SD; Mehta A; Dretler AW; Feldpausch A; Pavlick J; Spencer H; Ghinai I; Black SR; Hernandez-Guarin LN; Won SY; Shankaran S; Simms AT; Alarcón J; O'Shea JG; Brooks JT; McQuiston J; Honein MA; O'Connor SM; Chatham-Stephens K; O'Laughlin K; Rao AK; Raizes E; Gold JAW; Morris SB;
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1412-1417. PubMed ID: 36327164
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study.
Angelo KM; Smith T; Camprubí-Ferrer D; Balerdi-Sarasola L; Díaz Menéndez M; Servera-Negre G; Barkati S; Duvignaud A; Huber KLB; Chakravarti A; Bottieau E; Greenaway C; Grobusch MP; Mendes Pedro D; Asgeirsson H; Popescu CP; Martin C; Licitra C; de Frey A; Schwartz E; Beadsworth M; Lloveras S; Larsen CS; Guagliardo SAJ; Whitehill F; Huits R; Hamer DH; Kozarsky P; Libman M;
Lancet Infect Dis; 2023 Feb; 23(2):196-206. PubMed ID: 36216018
[TBL] [Abstract][Full Text] [Related]
19. Protocol of Tecopox study: a multicentre, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox or monkeypox.
Suzuki T; Saito S; Tsuzuki S; Ashida S; Takakusaki M; Yoshikawa T; Shimojima M; Ebihara H; Ohmagari N; Morioka S
BMJ Open; 2023 Aug; 13(8):e069550. PubMed ID: 37527886
[TBL] [Abstract][Full Text] [Related]
20. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
